Synergistic Effect of Metronomic Dosing of Cyclophosphamide Combined with Specific Antitumor Immunotherapy in a Murine Melanoma Model

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8408-8413

  Hermans, Ian F ^a   Chong, Tsung Wen ^a   Palmowski, Michael J ^a   Harris, Adrian L ^a   Cerundolo, Vincenzo ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; RECOMBINANT DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VACCINIA VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; H-2 ANTIGENS; HLA-A1 ANTIGEN; HLA-A2 ANTIGEN; LEUKOCYTE COUNT; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES, DNA; VACCINIA VIRUS;

EID: 0347626100     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature (Lond.), 411: 380-384, 2001.
2. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49: 281-355, 1991.
3. Askenase, P. W., Hayden, B. J., and Gershon, R. K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J. Exp. Med., 141: 697-702. 1975.
4. Maguire, H. C., Jr., and Ettore, V. L. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J. Investig. Dermatol., 48: 39-43, 1967.
5. Mitsuoka, A., Baba, M., and Morikawa, S. Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. Nature (Lond.), 262: 77-78, 1976.
6. Vierboom, M. P., Bos, G. M., Ooms, M., Offringa, R., and Melief, C. J. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int. J. Cancer. 87: 253-260, 2000.
7. Machiels, J. P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., and Jaffee, E. M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res., 61: 3689-3697, 2001.
8. Ehrke, M. J., Mihich, E., Berd, D., and Mastrangelo, M. J. Effects of anticancer drugs on the immune system in humans. Semin. Oncol., 16: 230-253, 1989.
9. Hengst, J. C., Mokyr, M. B., and Dray, S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res., 41: 2163-2167, 1981.
10. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
11. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastinc and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105: R15-24,2000.
12. Palmowski, M. J., Choi, E. M., Hermans, I. F., Gilbert, S. C., Chen, J. L., Gileadi, U., Salio, M., Van Pel, A., Man, S., Bonin, E., Liljestrom, P., Dunbar, P. R., and Cerundolo, V. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol., 168: 4391-4398, 2002.
13. Prevost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F. M., and Pircher, H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol., 161: 2187-2194, 1998.
14. Altman, J. D., Moss, P. A., Goulder, P. J., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Wash. DC), 274: 94-96, 1996.
15. Hanke, T., Neumann, V. C., Blanchard, T. J., Sweeney, P., Hill, A. V., Smith, G. L., and McMichael, A. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine, 17: 589-596, 1999.
16. Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L., and Hill, A. V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med., 4: 397-402, 1998.
17. Kent, S. J., Zhao, A., Best, S. J., Chandler, J. D., Boyle, D. B., and Ramshaw, I. A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol., 72: 10180-10188, 1998.
18. Carroll, M. W., Overwijk, W. W., Chamberlain, R. S., Rosenherg, S. A., Moss, B., and Restifo, N. P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 15: 387-394, 1997.
19. Harrington, L. E., Galvan, M., Baum, L. G., Altman, J. D., and Ahmed, R. Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J. Exp. Med., 191: 1241-1246, 2000.
20. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and Nakayama, E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res., 59: 3128-3133, 1999.
21. Shimizu, J., Yamazaki, S., and Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol., 163: 5211-5218, 1999.
22. Glaser, M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J. Exp. Med., 149: 774-779, 1979.
23. Giampietri, A., Bonmassar, A., Puccetti, P., Circolo, A., Goldin, A., and Bonmassar, E. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer imnmnotherapy. Cancer Res., 41: 681-687, 1981.
24. Tentori, L., Leonetti, C., Lozupone, F., and Bonmassar, E. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL). Cancer Immunol. Immunother., 41: 375-383, 1995.
25. Ibe, S., Qin, Z., Schuler, T., Preiss, S., and Blankenstein, T. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med., 194: 1549-1559, 2001.
26. Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Bohlen, P., Hicklin, D. J., Bergers, G., and Kerbel, R. S. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res., 62: 2731-2735, 2002.